PE-22-28 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
PE-22-28 is being researched for anxiety applications. Antagonizes TREK-1 (TWIK-related potassium channel), blocking potassium conductance to depolarize neurons and increase membrane excitability. Enhances serotonergic neuron firing and elevates monoamine. Common dosages for this use range from 100-500 mcg daily once daily.
Can PE-22-28 Help With Anxiety?
PE-22-28 (PE-22-28 (spadin analog, TREK-1 inhibitor)) is being researched for anxiety applications based on its mechanism as a Ion channel inhibitor peptide.
Antagonizes TREK-1 (TWIK-related potassium channel), blocking potassium conductance to depolarize neurons and increase membrane excitability. Enhances serotonergic neuron firing and elevates monoamine neurotransmission, producing rapid antidepressant effects within 4 days by stimulating hippocampal neurogenesis.
What Does the Research Show for PE-22-28 and Anxiety?
Superior TREK-1 inhibition (IC50: 0.12 nM vs 40-60 nM for native spadin) with rapid antidepressant effects in rodent stress models. 4-day onset compared to weeks for conventional antidepressants. No human clinical trials.
The relevance to anxiety specifically comes from PE-22-28's effects on rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs), hippocampal neurogenesis, enhanced synaptogenesis.
What Protocol Is Used for Anxiety?
For anxiety applications, the standard PE-22-28 protocol is 100-500 mcg daily administered once daily via subcutaneous injection (proposed) for 4-8 weeks.
Some researchers adjust dosing based on the specific anxiety application — see our PE-22-28 dosage guide for full protocol details.
Can Stacking Improve Anxiety Results?
Could theoretically pair with SSRIs for enhanced antidepressant effects through complementary serotonergic mechanisms.
What Side Effects Apply to Anxiety Use?
Minimal toxicity in animal models. Potential hypertension from enhanced monoamine activity. Human safety unknown. GABAergic disruption possible.
Side effects are generally consistent regardless of the specific application. See our PE-22-28 side effects guide for details.
Calculate Your PE-22-28 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for PE-22-28.
Open Calculator →Bottom Line: PE-22-28 for Anxiety
PE-22-28 shows preliminary research potential for anxiety. Standard protocols (100-500 mcg daily, once daily, 4-8 weeks) apply.
Source from COA-tested vendors and maintain consistent dosing for the full cycle duration.
Complete Guide
PE-22-28 : Benefits, Dosage, Side Effects & Research
Related Reading
- PE-22-28 Dosage Guide
- PE-22-28 Benefits
- PE-22-28 Side Effects
- PE-22-28 Stacking Guide
- PE-22-28 Cycle Guide
- PE-22-28 Research
Research-Grade Sourcing
If you're going to research PE-22-28, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is PE-22-28?
PE-22-28 (PE-22-28 (spadin analog, TREK-1 inhibitor)) is a Ion channel inhibitor peptide. Synthetic shortened analog of spadin with enhanced TREK-1 potassium channel specificity and brain stability. It is researched for rapid antidepressant effects (4 days vs 4-6 weeks for SSRIs), hippocampal neurogenesis, enhanced synaptogenesis.
What is the recommended PE-22-28 dosage?
Common dosages: 100-500 mcg daily administered once daily via subcutaneous injection (proposed). Cycle length: 4-8 weeks. Half-life: 14-23 hours in rodents. Use our peptide calculator for exact reconstitution math.
What are the side effects of PE-22-28?
Minimal toxicity in animal models. Potential hypertension from enhanced monoamine activity. Human safety unknown. GABAergic disruption possible.
Is PE-22-28 safe?
PE-22-28 has shown a preliminary safety profile in research. Not FDA-approved. Investigational research peptide only. All research should follow appropriate safety protocols.